Abstract

Methods of treating cancer, such as leukemia, via administration of therapeutically effective amounts of artemisinins and one or more additional therapeutic agents are detailed herein. The artemisinins include ART714. The one or more additional therapeutic agents include BCL-2 inhibitors such as ABT-199, ABT-263, and ABT-737; kinase inhibitors such as lestaurtinib, midostaurin, sorafenib, and gilteritinib; and anti-neoplastic agents such as cytarabine, doxorubicin, etoposide, cyclophosphamide, triplotide, vinorelbine, cisplatin, and rituximab.

IPC Classes  ?

• A61K 31/335 - Heterocyclic compounds having oxygen as the only ring hetero atom, e.g. fungichromin
• A61K 31/357 - Heterocyclic compounds having oxygen as the only ring hetero atom, e.g. fungichromin having two or more oxygen atoms in the same ring, e.g. crown ethers, guanadrel
• A61K 31/395 - Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
• A61K 31/496 - Non-condensed piperazines containing further heterocyclic rings, e.g. rifampin, thiothixene or sparfloxacin
• C07D 493/12 - Heterocyclic compounds containing oxygen atoms as the only ring hetero atoms in the condensed system in which the condensed system contains three hetero rings
• C07D 493/18 - Bridged systems
• C07K 31/33 -

Abstract

The present disclosure is directed to systems, compositions and methods for promoting immune tolerance to an antigen in a subject. Systems and methods provide for introducing directly into at least one lymph node(s) of the subject a therapeutically effective amount of a composition comprising an antigen associated with an autoimmune disease or disorder, in combination with a carrier comprising an immune modulatory agent such that an immune response to said antigen is inhibited or suppressed in the subject. The present disclosure is also directed to systems, compositions and methods for the treatment and/or prevention of autoimmune diseases and conditions, and in particular type 1 diabetes and graft rejection.

IPC Classes  ?

• A61P 37/06 - Immunosuppressants, e.g. drugs for graft rejection
• A61K 31/436 - Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with one nitrogen as the only ring hetero atom ortho- or peri-condensed with heterocyclic ring systems the heterocyclic ring system containing a six-membered ring having oxygen as a ring hetero atom, e.g. rapamycin
• A61P 37/02 - Immunomodulators
• A61K 39/00 - Medicinal preparations containing antigens or antibodies

Abstract

The present invention relates to the use of a condensate collector such as portable or stationary dehumidifier placed in a defined testing space or area and used as a readily available and affordable tool to collect airborne virus particles in collected condensate from the testing atmosphere in the defined testing space or area, wherein the collected condensate is analyzed for virus biomarkers to identify viruses, such as SARS-CoV-2 or mutants thereof in the testing atmosphere.

IPC Classes  ?

• G01N 1/40 - Concentrating samples
• G01N 1/22 - Devices for withdrawing samples in the gaseous state
• G01N 33/569 - ImmunoassayBiospecific binding assayMaterials therefor for microorganisms, e.g. protozoa, bacteria, viruses
• G01N 33/543 - ImmunoassayBiospecific binding assayMaterials therefor with an insoluble carrier for immobilising immunochemicals
• C12Q 1/70 - Measuring or testing processes involving enzymes, nucleic acids or microorganismsCompositions thereforProcesses of preparing such compositions involving virus or bacteriophage

Abstract

The present invention describes an integrated apparatus that enables identification of migratory cells directly from a specimen. The apparatus only requires a small number of cells to perform an assay and includes novel topographic features which can reliably differentiate between migratory and non-migratory cell populations in a sample. Both the spontaneous and chemotactic migration of cancer cells may be measured to distinguish between subpopulations within a tumor sample. The migratory cells identified using the apparatus and methods of the present invention may be separated and further analyzed to distinguish factors promoting metastasis within the population. Cells in the apparatus can be treated with chemotherapeutic or other agents to determine drug strategies to most strongly inhibit migration. The use of optically transparent materials in some embodiments allows a wide range of imaging techniques to be used for in situ imaging of migratory and non migratory cells in the apparatus. The apparatus and methods of the present invention are useful for predicting the metastatic propensity of tumor cells and selecting optimal drugs for personalized therapies.

IPC Classes  ?

• B01L 3/00 - Containers or dishes for laboratory use, e.g. laboratory glasswareDroppers
• G01N 33/50 - Chemical analysis of biological material, e.g. blood, urineTesting involving biospecific ligand binding methodsImmunological testing